$3.11
▲ +0.7% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
Overview
52-week range
$1.30
$6.94
32% of range
Avg surprise (last 3)
-18.5%
Avg reaction (last 2)
-7.8%
0% positive
Latest IV / EM
88%
EM ±20.2% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.28 | $-0.24 | -16.7% | +30.0% | -8.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.32 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.41 | $-0.36 | -13.9% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.40 | $-0.32 | -25.0% | — | -7.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.44 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.46 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.44 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.55 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.47 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.24 | -$0.41 | +41.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $1M | $1M | $1M | — | $209,000 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-51M | — | $-54M | $-53M | $-52M | — | $-54M | $-56M |
| Net income | $-49M | — | $-51M | $-53M | $-52M | — | $-53M | $-55M |
| EPS (diluted) | $-0.28 | — | $-0.32 | $-0.41 | $-0.40 | — | $-0.44 | $-0.46 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $64M | $63M | $71M | $54M | $92M | $182M | $118M | $56M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $138M | $181M | $231M | $121M | $164M | $212M | $246M | $171M |
| Total assets | $295M | $343M | $385M | $279M | $328M | $298M | $333M | $260M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $218M | $222M | $223M | $218M | $221M | $144M | $143M | $63M |
| Total equity | $77M | $121M | $162M | $61M | $107M | $153M | $190M | $197M |